An Open-label, Multi-center, Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available
Phase of Trial: Phase III
Latest Information Update: 12 Jan 2018
At a glance
- Drugs Ruxolitinib (Primary)
- Indications Polycythaemia vera
- Focus Adverse reactions; Expanded access
- Sponsors Novartis
- 12 Jan 2018 This trial has been completed in Bulgaria.
- 12 Dec 2017 Safety and efficacy results (n=75; data cutoff: Jan 15, 2017) presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 16 Jun 2017 Planned End Date changed from 31 Dec 2017 to 1 Jan 2018.